Salmen A, Chan A
Fortschr Neurol Psychiatr. 2015 Mar;83(3):174-86. doi: 10.1055/s-0034-1399247. Epub 2015 Mar 20.
Therapeutic options in the treatment of multiple sclerosis (MS) have broadened notably over the past years, especially for relapsing-remitting forms of MS. The revision of the diagnostic criteria simplified and accelerated MS diagnosis, definitions of disease courses were operationalized focussing on disease activity and progression as major determinants. The paradigm of an early treatment initiation is accepted and evidence-based. All these aspects have led to an increasing complexity of therapeutic decision making. Besides a benefit-risk-evaluation for each substance, individual patient-related factors have to be considered, e.g. life and family planning. This article reviews new and established disease-modifying drugs in the context of disease courses and stages and benefit-risk-considerations.
在过去几年中，多发性硬化症（MS）的治疗选择显著增加，尤其是对于复发缓解型MS。诊断标准的修订简化并加速了MS的诊断，疾病进程的定义围绕疾病活动和进展这两个主要决定因素进行了细化。早期开始治疗的模式已被接受且有循证依据。所有这些方面都导致治疗决策的复杂性日益增加。除了对每种药物进行获益-风险评估外，还必须考虑个体患者相关因素，例如生活和计划生育。本文在疾病进程和阶段以及获益-风险考量的背景下，综述了新型和已有的疾病修饰药物。
